CN102579496A - Acupoint injection biological drug - Google Patents
Acupoint injection biological drug Download PDFInfo
- Publication number
- CN102579496A CN102579496A CN2012100892194A CN201210089219A CN102579496A CN 102579496 A CN102579496 A CN 102579496A CN 2012100892194 A CN2012100892194 A CN 2012100892194A CN 201210089219 A CN201210089219 A CN 201210089219A CN 102579496 A CN102579496 A CN 102579496A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- acupoint injection
- suspension
- biological drug
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of mesenchymal stem cells in preparing acupoint injection biological drug and acupoint injection biological drug. The acupoint injection biological drug is composed of physiological saline solution suspension, vitamin B1 and vitamin B12, wherein the volume rate of the suspension : the vitamin B1 : the vitamin B12 is 10-15 : 1-10 : 1-10, and the suspension contains cells of 2*107 to 10*107 per 10mL. The acupoint injection biological drug adopts traditional Chinese medicine methods and formulation design to finish treatment of stem cell technology on diseases, thereby being simple and safe in operation method, obvious and effective in treatment and capable of achieving breakthrough of treatment of stem cell technology on diseases and facilitating development of acupoint injection technology.
Description
Technical field
The present invention relates to medical technical field, relate in particular to a kind of biological agent that is used for acupoint injection therapy.
Background technology
Mescenchymal stem cell is one type and derives from growth early stage mesoderm and ectodermic pluripotent stem cell; Mainly be present between connective tissue and organ in the matter; Have multidirectional differentiation potential, hemopoietic support and promote characteristics such as stem cell implantation, immunoregulation and self replication, be proved can treat many clinically like difficult diseases such as end-age cirrhosis, diabetic complication, myocardial infarction, autoimmune diseasees.At present, adopt the mode of mescenchymal stem cell treatment disease to be generally intravenous injection, intra-arterial injection, spinal cord intracavitary administration etc. in the world wide.Yet the intravenous injection time is longer, and it is active and affect the treatment to lose part at the time inner cell of injection.The arterial perfusion stem cell need carry out arterial cannulation, complicated operation and have corresponding risk, and the patient is difficult for accepting.The spinal cord intracavitary administration belongs to local application's method, has the limitation of corresponding diseased region treatment, need have corresponding risk equally than complicated technology simultaneously, and the patient is difficult for accepting.
The acupoint injection therapy technology is to be the basis with traditional Chinese medical science tradition meridian theory, and medicine is injected a kind of method of relevant acupoints with the treatment disease.At present; Acupoint injection therapy is to adopt Chinese herbal and crude drugs preparations mostly, like traditional medicine Injectios such as Radix Angelicae Sinensis, Radix Ginseng Rubra, although this technical development has the history in year surplus in the of 40 so far; Have and simply be convenient to the characteristics of operating; Be used to treat the chronic disease of multiple difficulty, but how furtherd investigate the development of studying the acupoint injection therapy technology and promoting this technology, remained the problem that present urgent need solves.
At present, find as yet to have that pharmaceutical preparation is used for clinical report as acupoint injection therapy with mescenchymal stem cell.
Summary of the invention
The objective of the invention is to overcome the deficiency of prior art; Providing a kind of is biological agent main, that be applicable to acupoint injection therapy with the mescenchymal stem cell; To realize the breakthrough of stem cell disease treatment technology; Effectively improve the effect and the effect of stem cell disease treatment, and promote the development of acupoint injection therapy technology.
The object of the invention is achieved through following technical scheme:
The present invention provides the application of mescenchymal stem cell in preparation acupoint injection therapy with medicament.
A kind of acupoint injection therapy biological agent provided by the invention; Normal saline suspension, vitamin B1, vitamin B12 by mescenchymal stem cell are formed; Each volume ratio of forming is a suspension: vitamin B1: vitamin B12=10～15: 1～10: 1～10, and said suspension contains cell 2 * 10
7～10 * 10
7Individual/10mL.Preferred version is that said each volume ratio of forming is a suspension: vitamin B1: vitamin B12=10: 1: 1, said suspension contains cell 3 * 10
7Individual/10mL.
The present invention adopts the Chinese medicine means, through recipe design, accomplishes stem cells technology to treatment of diseases.Simple, the safety of operational approach, the patient is easy to accept, and save time, produce effects is fast, avoided the loss of cytoactive, persistent, evident in efficacy.
To combine embodiment that the present invention is made further detailed description below.
The specific embodiment
One, the preparation of biological agent
Mescenchymal stem cell derives from the umbilical cord of healthy newborn, mixes with normal saline to form the 10mL suspension, wherein contains cell 3 * 10
7Individual; Add vitamin B1, each 1mL mix homogeneously of vitamin B12 then.
Two, clinical experimental study
With the treatment liver cirrhosis is example.
1, physical data
Case source: cirrhosis patients in decompensation patient's 32 examples, wherein, liver cirrhosis due to hbv patient 25 examples, alcoholic cirrhosis 4 examples, schistosoma liver 3 examples of hardening are pressed the Child classification: B level 6 examples, C level 26 examples.Male's 25 examples, women's 7 examples, 28～68 years old age.
2, diagnosis situation
Sings and symptomses such as that all patients all exist is weak, poor appetite, abdominal distention, ascites and edema of lower limbs, the functional parameter diagnosis meets " viral hepatitis is prevented and treated scheme " (2005) and " liver failure practice guidelines " (2006) diagnostic criteria.
3, Therapeutic Method
Get patient's sp 6, the sea of blood, Quchi acupuncture point, left-right symmetric is totally 6 acupuncture points then.According to the patient's body situation, the above-mentioned biological agent of 1～2mL is injected at each acupuncture point.
4, curative effect situation
(1) liver function and coagulation function index
With postoperative 2,4,8,12 all liver functions and coagulation function index (seeing table 1 and table 2), (x ± s) expression relatively adopts paired t-test to data before and after the same patient treatment, employing SPSS13.0 software analysis with mean ± standard deviation before the difference detection technique.
Table 1 preoperative and postoperative changes of liver function situation
| Project | Before the art | 2 weeks of postoperative | 4 weeks of postoperative | 8 weeks of postoperative | 12 weeks of postoperative |
| Albumin g/L | 27.05±5.23 | 27.62±4.02 | 39.02±5.02 * | 38.25±3.69 * | 39.10±6.11 * |
| STB umol/L | 26.01±13.05 | 27.11±12.70 | 26.39±11.0 | 22.81±13.0 | 20.21±13.12 |
| Glutamate pyruvate transaminase U/L | 44.63±22.23 | 44.63±22.23 | 39.28±33.31 | 38.94±36.89 | 38.63±22.23 |
| Glutamic oxaloacetic transaminase, GOT U/L | 71.17 soil 37.31 | 78.29±78.03 | 77.96±69.63 | 62.33±38.28 | 49.82±38.55 |
| Cholinesterase U/L | 2186.04±1688.35 | 2841.83±1661.29 | 3352.94±2025.69 | 4585.00±1879.208 * | 4964.07±1814.79 * |
| TOTAL BILE ACID TBA umol/L | 78.00±59.80 | 73.17±54.81 | 63.22±55.81 | 62.78±45.62 | 41.63±33.91 * |
| Alpha-fetoprotein ug/L | 10.03±3.91 | 11.63±4.51 | 8.63±4.91 | 7.63±5.01 ** | 7.60±3.21 * |
Annotate: compare respectively with before the art,
*Expression P＜0.05,
*P＜0.01.
Table 2 preoperative and postoperative coagulation function situation of change
| Project | Before the art | 2 weeks of postoperative | 4 weeks of postoperative | 8 weeks of postoperative | 12 weeks of postoperative |
| Thrombinogen s | 24.05±5.23 | 22.45±4.23 | 17.05±5.13 * | 15.05±4.23 ** | 16.05±2.23 ** |
| Fibrin g/L | 1.55±0.53 | 1.85±0.93 | 2.55±0.53 ** | 2.65±0.43 ** | 2.35±0.23 ** |
| Platelet count 10 9/L | 57.15±15.23 | 57.55±15.53 | 58.05±16.03 | 77.85±14.23 | 90.81±13.23 |
Annotate: compare respectively with before the art,
*Expression P＜0.05,
*P＜0.01.
Above result shows that behind the acupoint injection therapy stem-cell therapy, patient's albumin obviously raises, and transaminase's index descends, and liver function is improved, and coagulation function improves.
(2) symptom and sign
Improve in 1 week of postoperative and see that at most 93.8% (30 example) patient obviously improves with appetite, muscle power; The 2nd week 93.8% (30 example) patient hepatic facies occurs and takes a turn for the better; 96.9% (31 example) the patient's ascites disappearance of the 4th week.
5, case case index situation of change
Case: Deng, the man, 55 years old, go into section's treatment because of posthepatitic cirrhosis, after diagnosing for posthepatitic cirrhosis loses the compensatory phase, be hypoproteinemia, indirect inguinal hernia (left side).Get patient's sp 6, the sea of blood, Quchi acupuncture point, left-right symmetric is totally 6 acupuncture points then, and the above-mentioned biological agent of 2mL is injected at each acupuncture point.Table 3 and table 4 are seen in the liver biochemistry inspection index variation and the routine blood test variation that reach postoperative before patient's art.
Table 3 liver biochemistry inspection situation of change
Table 4 routine blood test situation of change
This patient's postoperative albumin significantly raises, and appetite is improved, and the state of an illness is clearly better.Urine amount showed increased, its anteroposterior trunk diameter (dorsal position): be 22cm the same day before the art, and postoperative 9 days was 16cm; Abdominal circumference: be 86cm the same day before the art, and postoperative 6 days was 81cm, and postoperative 9 days was 77cm.
Claims (3)
1. the application of mescenchymal stem cell in preparation acupoint injection therapy with medicament.
2. acupoint injection therapy biological agent; It is characterized in that: normal saline suspension, vitamin B1, vitamin B12 by mescenchymal stem cell are formed; Each volume ratio of forming is a suspension: vitamin B1: vitamin B12=10～15: 1～10: 1～10, and said suspension contains cell 2 * 10
7～10 * 10
7Individual/10mL.
3. acupoint injection therapy biological agent according to claim 2 is characterized in that: said each volume ratio of forming is a suspension: vitamin B1: vitamin B12=10: 1: 1, said suspension contains cell 3 * 10
7Individual/10mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100892194A CN102579496A (en) | 2012-03-30 | 2012-03-30 | Acupoint injection biological drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100892194A CN102579496A (en) | 2012-03-30 | 2012-03-30 | Acupoint injection biological drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579496A true CN102579496A (en) | 2012-07-18 |
Family
ID=46469101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100892194A Pending CN102579496A (en) | 2012-03-30 | 2012-03-30 | Acupoint injection biological drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579496A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150093367A1 (en) * | 2013-09-27 | 2015-04-02 | Global Health Solutions Research Trust | Acupoint injection therapy using an enriched cellular mixture |
| CN111803520A (en) * | 2020-07-27 | 2020-10-23 | 杭州嘉耀健康管理有限公司 | Acupoint injection for improving immune function |
-
2012
- 2012-03-30 CN CN2012100892194A patent/CN102579496A/en active Pending
Non-Patent Citations (5)
| Title |
|---|
| 《Journal of Gastroenterology and Hepatoloty》 20120209 Fu-Sheng Wang "Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients." 112-120 2-3 第27卷, 第S2期 * |
| 《中国组织工程研究与临床康复》 20081021 张哲等 "同种异体骨髓间充质干细胞穴位移植对梗死心肌及周围区细胞凋亡及相关蛋白的影响" 8477-8480 1-3 第12卷, 第43期 * |
| FU-SHENG WANG: ""Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients."", 《JOURNAL OF GASTROENTEROLOGY AND HEPATOLOTY》 * |
| 张哲等: ""同种异体骨髓间充质干细胞穴位移植对梗死心肌及周围区细胞凋亡及相关蛋白的影响"", 《中国组织工程研究与临床康复》 * |
| 许冀陕，白波: "《消化病用药备忘录》", 31 March 2008, 人民军医出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150093367A1 (en) * | 2013-09-27 | 2015-04-02 | Global Health Solutions Research Trust | Acupoint injection therapy using an enriched cellular mixture |
| CN111803520A (en) * | 2020-07-27 | 2020-10-23 | 杭州嘉耀健康管理有限公司 | Acupoint injection for improving immune function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772407B (en) | Pharmaceutical composition for promoting nerve damage restoration and application thereof | |
| CN102940853B (en) | Navel paste for treating mammary gland hyperplasia diseases | |
| CN103861079B (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN108653263A (en) | Purposes of the chlorogenic acid and combinations thereof in the drug for preparing treatment sarcoma | |
| CN102579496A (en) | Acupoint injection biological drug | |
| CN102579999A (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN104043045A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN102188699A (en) | Pharmaceutical composition for treating atherosclerosis, and preparation method and application thereof | |
| CN102813914B (en) | Medicinal composition used for treating or preventing cerebrovascular disease and related diseases | |
| CN102302710A (en) | Chinese medicinal preparation for treating various arthralgia syndromes | |
| Wang et al. | Ligustrazine and Salvia miltiorrhiza injection solution in complementary therapy of pregnancy-induced hypertension: clinical analysis of 60 cases | |
| CN102240302A (en) | Chinese medicine composition of super gene active peptide | |
| CN101485669A (en) | Medicament for treating tumor and hemorrhoid and method for producing the same | |
| CN104800264B (en) | One kind carries medicine acupuncture needle and application thereof | |
| Afreen et al. | Therapeutic uses of earthworm–a review | |
| CN2768163Y (en) | Fixing device for improving hepar targeted medicament curing effect | |
| CN104825563A (en) | Traditional Chinese medicine preparation for treating cervical spondylosis and preparation method thereof | |
| CN104055777B (en) | A kind of freeze-drying medicinal composition containing methionine vitamin B 1 | |
| CN107184912A (en) | The positive disperse accumulations compound preparation of one breeding and its application | |
| Zhang et al. | Therapeutic observation of ‘warming-unblocking needling technique’for knee osteoarthritis due to deficiency of liver and kidney | |
| CN105816862A (en) | Application of ulinastatin in preparation of drugs for treating prostatic cancer | |
| CN105797144B (en) | Purposes of the composition containing ulinastatin in preparation treatment prostatitis drug | |
| CN105770876B (en) | Purposes of the ulinastatin in preparation treatment chronic prostatitis drug | |
| CN114949086A (en) | Composition for treating cerebral hemorrhage | |
| Liu | ZTTTkkS Open Access |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120718 |